New ISACA Guide Outlines Key Components of Digital Trust Implementation
4.5.2022 16:30:00 EEST | Business Wire | Press release
While we may not always realize it, most of our interactions as consumers create a digital footprint—whether we are paying a friend through a mobile app or registering online for a doctor’s appointment. But can we always trust that our transactions and interactions in these digital ecosystems will be conducted with integrity? A new complimentary white paper from ISACA, Digital Trust: A Modern-Day Imperative, explores this increasingly important concept of digital trust, how it relates to both consumers and providers, and how it works in practice.
Digital Trust provides a detailed definition of digital trust—the confidence in the integrity of the relationships, interactions and transactions among suppliers/providers and customers/consumers within an associated digital ecosystem—and examines how imperative it is for enterprises to build and maintain this trust.
The paper, launched at the ISACA Conference North America today, is the first resource in ISACA’s new digital trust strategy.
“Think about a digital space with fewer attacks, more innovation and business growth, and enhanced confidence, with IT professionals leading the way,” said ISACA CEO David Samuelson. “Our global community of like-minded IT professionals works in pursuit of digital trust. More trust means more success. And as security, privacy, assurance and quality professionals, the ISACA community is a key enabler of that success.”
The Digital Trust paper outlines how consumers consider six key elements when assessing digital trust:
- Quality
- Availability
- Security and privacy
- Ethics and integrity
- Transparency and honesty
- Stability and resilience
Many enterprises already realize that valuing digital trust provides them with a competitive advantage, both with their reputation and bottom line. Digital Trust outlines some of the ways that providers can put digital trust in practice, including:
- Refraining from using dark patterns or techniques to trick or influence data subjects to make a specific choice
- Conducting regular audits to ensure that controls are in place and working as they should
- Providing employees with trustworthy technology to do their jobs, and not monitoring them without their knowledge or consent.
“It is absolutely critical for digital trust to be woven into the fabric of any enterprise—to avoid harmful security and privacy incidents, strengthen relationships with consumers, and advance reputation and the bottom line,” says Mark Thomas, president, Escoute Consulting. “Professionals who work in security, audit, governance, risk or privacy all play an essential role in driving digital trust forward, so it is vital that each understands their part in establishing, evaluating, adjusting and implementing digital trust practices within their organizations.”
To download a complimentary copy of the white paper, visit www.isaca.org/digital-trust. ISACA will release additional digital trust resources later this year, including a course, webinar, global research and digital trust framework.
Additional information on ISACA’s digital trust strategy is available in this ISACA Now blog post from ISACA CEO David Samuelson here.
About ISACA
For more than 50 years, ISACA® (www.isaca.org) has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enabled enterprises to train and build quality teams. A global professional association and learning organization, ISACA leverages the expertise of its more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005723/en/
Contact information
Emily Van Camp, evcamp@isaca.org, +1.847.385.7223
Kristen Kessinger, communications@isaca.org, +1.847.660.5512
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
